Last updated: December 31, 2024
Introduction
Mirabegron, with the National Drug Code (NDC) 70710-1159, is a medication manufactured and distributed by Zydus Pharmaceuticals (USA) Inc. It is used primarily for the treatment of overactive bladder symptoms. Here is a comprehensive market analysis and price projection for this drug.
Overview of Mirabegron
Mirabegron is a beta-3 adrenergic agonist that helps relax the bladder muscle during the storage of urine, thereby increasing the bladder capacity and reducing the urgency to urinate. It is available in various strengths, but the specific NDC 70710-1159 refers to a particular formulation and strength of the drug[2].
Market Demand
The demand for mirabegron is driven by the prevalence of overactive bladder (OAB) and the need for effective treatments. OAB affects a significant portion of the adult population, particularly among older adults. As the global population ages, the demand for medications like mirabegron is expected to increase.
Competitive Landscape
The market for OAB treatments includes both brand-name and generic drugs. Mirabegron, being a generic version, competes with other generic and brand-name medications such as oxybutynin and tolterodine. The competitive landscape is influenced by factors such as efficacy, side effect profile, and pricing. Zydus Pharmaceuticals, as a generic drug manufacturer, benefits from the lower cost structure compared to brand-name drugs, making mirabegron an attractive option for patients and healthcare providers[2].
Pricing Factors
Several factors influence the pricing of mirabegron:
Regulatory Environment
Regulations such as the Prescription Drug Price Transparency Act aim to increase transparency in drug pricing. This can impact how manufacturers set prices, as they must report price increases and justify them to regulatory bodies[3].
Manufacturing Costs
The cost of production, including research and development expenses, plays a crucial role in determining the final price of the drug.
Market Competition
The presence of other generic and brand-name drugs in the market affects pricing. Generic drugs like mirabegron typically offer a more affordable alternative, which can drive down prices.
Rebates and Discounts
Pharmaceutical companies often offer rebates and discounts to health insurance companies and pharmacies, which can reduce the final cost to the consumer[3].
Price Projections
Given the current market dynamics, here are some key points to consider for price projections:
Current Pricing
As of the latest data, the pricing for mirabegron can vary based on the region, insurance coverage, and pharmacy. However, generic drugs are generally priced lower than their brand-name counterparts.
Future Trends
- Increased Transparency: With increased regulatory scrutiny, there may be more pressure on manufacturers to justify price increases, potentially stabilizing or reducing prices[3].
- Market Competition: The entry of new generic competitors could further reduce prices.
- Demographic Changes: An aging population may increase demand, but this could also lead to more competitive pricing to capture market share.
Statistical Insights
- Annual price increases for prescription drugs, including generics, often range between 10% to 20%[3].
- However, for generic drugs, the price trend is generally more stable or decreasing due to competition.
Example Pricing Scenario
Assuming the current price of mirabegron (NDC 70710-1159) is around $50 per month for a standard prescription, here are some possible price projections:
- Short-term (2025-2026): Prices might remain stable or see a slight decrease due to increased competition and regulatory pressures.
- Projected price: $45-$50 per month.
- Medium-term (2027-2029): As more generic versions enter the market, prices could decrease further.
- Projected price: $40-$45 per month.
- Long-term (2030 and beyond): Continued competition and regulatory oversight could lead to even lower prices.
- Projected price: $35-$40 per month.
Key Takeaways
- The demand for mirabegron is expected to increase due to the growing prevalence of overactive bladder.
- Pricing is influenced by regulatory transparency, manufacturing costs, market competition, and rebates.
- Future price projections indicate a stable or decreasing trend due to competition and regulatory pressures.
FAQs
What is mirabegron used for?
Mirabegron is used to treat overactive bladder symptoms, including urgency, frequency, and incontinence.
Who manufactures mirabegron with NDC 70710-1159?
Zydus Pharmaceuticals (USA) Inc. manufactures mirabegron with the NDC 70710-1159.
How does the regulatory environment affect drug pricing?
Regulations like the Prescription Drug Price Transparency Act require manufacturers to report and justify price increases, which can stabilize or reduce prices.
What factors influence the pricing of mirabegron?
Pricing is influenced by manufacturing costs, market competition, rebates, and discounts, as well as regulatory requirements.
What are the projected price trends for mirabegron?
Prices are expected to remain stable or decrease slightly in the short term and more significantly in the medium to long term due to increased competition and regulatory pressures.
Sources
- FDA Report: NDC 70710-1121 Oral Tablet, Film Coated Doxycycline.
- Find-A-Code: Zydus Pharmaceuticals USA Inc. - List of Drugs.
- Oregon Department of Consumer and Business Services: Prescription Drug Price Transparency Results and Recommendations.
- FDA Report: NDC 70710-1459 Oral Powder, For Suspension Azithromycin Drug.
